Stock NBY NOVABAY PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus NovaBay Pharmaceuticals, Inc.

Equities

NBY

US66987P4090

Market Closed - Nyse
Other stock markets
 16:00:00 2024-06-14 EDT 		5-day change 1st Jan Change
2.51 USD -2.33% Intraday chart for NovaBay Pharmaceuticals, Inc. -7.38% -64.85%
05-09 NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-09 Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M MT

Evolution of the average Target Price on NovaBay Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0eadbf24a217ca61ed60e9d83eee61.3Qe-uEIl4F2PnOhXoIMgi9GjKZER1Nkql9hakYcamv4.mTX48jFIqRXc2N0imdNE3LaWGetSvpFI4Yo5-cJL7p-Fd-_pI0uMMOvfpQ~44c9ad8445d376a51b6753329765102d

Analyst Recommendations on NovaBay Pharmaceuticals, Inc.

Ladenburg Thalmann Cuts Price Target on NovaBay Pharmaceuticals to $3.80 From $6, Maintains Buy Rating MT
NOVABAY PHARMACEUTICALS : Ladenburg Thalmann Adjusts NovaBay Pharmaceuticals PT to $2.20 From $1.90, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.51 USD
Average target price
58.62 USD
Spread / Average Target
+2,235.66%
High Price Target
61.25 USD
Spread / Highest target
+2,340.24%
Low Price Target
56 USD
Spread / Lowest Target
+2,131.08%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NovaBay Pharmaceuticals, Inc.

Ladenburg Thalmann

Ratings for NovaBay Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NBY Stock
  4. Consensus NovaBay Pharmaceuticals, Inc.